Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9545426 | ACACIA | Use of amisulpride as an anti-emetic |
Mar, 2031
(7 years from now) | |
US9889118 | ACACIA | Use of amisulpride as an anti-emetic |
Mar, 2031
(7 years from now) | |
US10525033 | ACACIA | Use of amisulpride as an anti-emetic |
Mar, 2031
(7 years from now) | |
US9084765 | ACACIA | Use of amisulpride as an anti-emetic |
Feb, 2034
(10 years from now) | |
US11357753 | ACACIA | Rescue treatment of post operative nausea and vomiting |
Feb, 2038
(14 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Feb 26, 2025 |
NCE-1 date: 2024-02-27
Market Authorisation Date: 26 February, 2020
Treatment: Prevention of post-operative nausea and vomiting; Treatment of post-operative nausea and vomiting
Dosage: SOLUTION;INTRAVENOUS
11
United States
4
United Kingdom
4
European Union
3
Israel
3
Denmark
3
Mexico
3
Slovenia
3
Croatia
3
Portugal
3
Cyprus
3
Spain
3
Poland
3
RS
3
Japan
2
Australia
2
Brazil
2
Korea, Republic of
2
San Marino
2
China
2
EA
2
Canada
1
Hong Kong
1
Lithuania
1
Hungary
1
Norway
1
New Zealand
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic